scispace - formally typeset
Y

Yasuaki Ogawa

Researcher at Takeda Pharmaceutical Company

Publications -  97
Citations -  4242

Yasuaki Ogawa is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Glycolic acid & Liposome. The author has an hindex of 34, co-authored 97 publications receiving 4165 citations. Previous affiliations of Yasuaki Ogawa include Wako Pure Chemical Industries, Ltd.

Papers
More filters
Journal ArticleDOI

Rates of Systemic Degradation and Reticuloendothelial System (RES) Uptake of Thermosensitive Liposome Encapsulating Cisplatin in Rats

TL;DR: The kinetic analysis demonstrated that the RES uptake rate was almost the same among the liposomes, while the systemic degradation rate became larger as the content of DSPC decreased and the Kdeg for each type of liposome corresponded with the systemic CDDP release rate.
Journal ArticleDOI

A one-step enzyme-linked immunosorbent assay for a novel osteoblast differentiation-promoting compound, TAK-778 in serum.

TL;DR: The present ELISA is so rapid, sensitive and selective for TAK-778 that it could be conveniently used in a clinical field for the determination of many serum specimens.
Patent

Compositions based on hyaluronic acid

TL;DR: A water-soluble composition which comprises a pharmacologically active polypeptide, erythropoietin, secreted by an animal body or its derivative or a chemically synthesized pharmacological active substance, such as hyaluronic acid or its nontoxic salt, and injectable into body fluids without showing any substantial pharmacological activity brings about a prolonged action in vivo of a pharmaceutical active substance as mentioned in this paper.
Journal ArticleDOI

Enhancement of the Anti-tumor Activity of Recombinant Interleukin-2 (rIL-2) by Immunocomplexing with an F (ab') 2 Fragment of Murine Monoclonal Antibody against rIL-2

TL;DR: The biological properties of an immune complex composed of recombinant interleukin-2 and an F(ab')2 fragment of a monoclonal antibody against rIL-2 in mice for the induction of killer cells and anti-tumor activity are investigated, as well as the pharmacokinetic properties of the immune complex injected subcutaneously into mice.
Journal ArticleDOI

A Sensitive ELISA for the Characterization of Two Forms of Circulating Intercellular Adhesion Molecule-1 in Human Plasma

TL;DR: The result from the gel electrophoresis employing Western blotting suggests that ICAM-1 circulates in at least two molecular forms with molecular masses of about 85 and 130 kDa and with different reactivities to WIS2-11 and WIS5-85.